Evidence map›Paper›PMID 40857162›Full record

ArticleAmerican journal of physiology. Renal physiology2025

MARY1 restores mitochondrial homeostasis and accelerates renal recovery following acute kidney injury.

Paul Victor Santiago Raj, Jaroslav Janda, Natalie E Scholpa, Kevin A Hurtado, Rick G Schnellmann

Abstract read
In one paragraph

Article in American journal of physiology. Renal physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Paul Victor Santiago RajDepartment of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, University of Arizona, Tucson, Arizona, United States.ORCID 0000-0001-6376-5930
Jaroslav JandaDepartment of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, University of Arizona, Tucson, Arizona, United States.
Natalie E ScholpaDepartment of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, University of Arizona, Tucson, Arizona, United States.ORCID 0000-0002-1234-5482
Kevin A HurtadoDepartment of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, University of Arizona, Tucson, Arizona, United States.ORCID 0000-0002-8237-414X
Rick G SchnellmannDepartment of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, University of Arizona, Tucson, Arizona, United States.ORCID 0000-0001-6226-6064

Funding

BLRD VA I01 BX000851BLRD VA IK2 BX005218U.S. Department of Veterans Affairs (VA) BX000851U.S. Department of Veterans Affairs (VA) BX005218
6 · The paper itself

Abstract

Acute kidney injury (AKI) is a major clinical concern with limited therapeutic strategies, often leading to chronic kidney disease (CKD) and long-term morbidity. Mitochondrial dysfunction is a major causative factor for AKI onset and progression to CKD. Interventions that restore mitochondrial integrity and cellular energy represent promising therapeutic strategies. This study investigated the potential therapeutic role of MARY1, a novel, potent, and subtype-selective serotonin-2B receptor (5-HT

Indexed as

Acute Kidney InjuryKidneyMitochondriaReperfusion InjurySerotonin 5-HT2 Receptor AntagonistsAnimalsAutophagyDisease Models, AnimalHomeostasisMaleMiceMice, Inbred C57BLOrganelle BiogenesisRatsRats, Sprague-DawleyRecovery of FunctionSerotonin 5-HT2 Receptor Antagonists5-hydroxytryptamine 2B receptor antagonismacute kidney injurymitochondrial dysfunctionrenal function

Identifiers

PMID40857162
PMCPMC12462716

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.